DeCure's autonomous Rare AI scientist is researching a drug-repurposing hypothesis for Li-Fraumeni syndrome — screening already-approved drugs against its 6-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleLi-Fraumeni syndrome maps to a 6-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for li-fraumeni syndrome is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
Molecular view
MDM2 proto-oncogene (MDM2) — MDM2 is one of the genes genetically linked to this disease in Open Targets — shown as context, not as a drug target we're pursuing: no approved-drug candidate for this disease is yet corroborated in the literature we found.
Loading structure…
helix sheet {6-[(6-chloro-3-{1-[(4-chlorophenyldrag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 5J7F · 2.0 Å · ligand 4-({6-[(6-chloro-3-{1-[(4-chlorophenyl)methyl]-4-(4-fluorophenyl)-1H-imidazol-5-yl}-1H-indole-2-carbonyl)oxy]hexyl}amino)-4-oxobutanoic acid (6GG). Experimental structure, not a prediction.
What the evidence adds up to
A 2016 case report describes a 57-year-old Chinese woman with concurrent squamous cell carcinoma, mucoepidermoid carcinoma, brain cancer, bone cancer, and thyroid cancer. Whole exome sequencing of DNA from thyroid, lung, and skin tumours and from normal thyroid tissue showed that the somatic mutations in the three tumour tissues differed notably, indicating the cancers arose independently rather than from metastasis. A novel deleterious germline mutation in CHEK2, a Li-Fraumeni syndrome causal gene, was identified (chr22:29091846, G->A, p.H371Y). Testing of the patient’s healthy siblings showed the mutation was de novo. This is the first reported Li-Fraumeni syndrome-like case in a Chinese patient.
A 2018 case report describes a 56-year-old woman with Li-Fraumeni syndrome who developed breast implant-associated anaplastic large cell lymphoma (BIA-ALCL) after prophylactic adenomastectomy with implant reconstruction. She presented with late right-sided recurrent breast swelling. Imaging showed a heterogeneous mass adjacent to the implant fibrous capsule, and biopsy confirmed BIA-ALCL. The authors note this is the second report of BIA-ALCL arising in the setting of Li-Fraumeni syndrome.
A 2023 case report describes a patient with Li-Fraumeni syndrome who developed synchronous non-small cell lung cancer (NSCLC) with both EGFR exon 19 deletion and EGFR exon 20 insertion mutations. Osimertinib was effective against the EGFR deletion 19 population but did not produce a response in the EGFR exon 20 insertion population, which was treated with surgical resection. At oligoprogression, the patient underwent surgical resection and minimised radiation therapy. The authors state the biologic link between Li-Fraumeni syndrome and EGFR mutation remains unclear.
No controlled trials, no prospective data on drug repurposing, and no survival or response rates beyond the single osimertinib case are available. What is missing is any systematic trial design, patient stratification by TP53 or CHEK2 mutation type, and funding for a registry or interventional study in this rare, genetically heterogeneous syndrome.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
Diagnostic Pathology · 2018 · 45 citations · open access
Breast implant-associated anaplastic large cell lymphoma in a Li-FRAUMENI patient: a case report
AbstractBACKGROUND: Breast implant-associated anaplastic large cell lymphoma (BIA-ALCL) is a rare malignancy, recently recognized as a provisional entity by the World Health Organization. Although increasing data have been published on this entity in recent years, a great number of patients and health professionals remain unaware of this diagnosis. CASE PRESENTATION: We herein report the case of a 56-year-old female with Li-FRAUMENI syndrome who presented with late right-sided recurrent breast swelling after prophylactic adenomastectomy with implant reconstruction. Imaging scans revealed an heterogeneous mass adjacent to the implant fibrous capsule. A biopsy of the lesion rendered the diagnosis of a BIA-ALCL. CONCLUSIONS: This case presents similarities with previous reports, but also some particularities, which should be stressed in order to make the diagnosis the earliest possible. The most distinct feature is that this is the second report of BIA-ALCL arising in the setting of Li-FRAUMENI syndrome.
Case report of a Li–Fraumeni syndrome-like phenotype with a de novo mutation in CHEK2
AbstractBACKGROUND: Cases of multiple tumors are rarely reported in China. In our study, a 57-year-old female patient had concurrent squamous cell carcinoma, mucoepidermoid carcinoma, brain cancer, bone cancer, and thyroid cancer, which has rarely been reported to date. METHODS: To determine the relationship among these multiple cancers, available DNA samples from the thyroid, lung, and skin tumors and from normal thyroid tissue were sequenced using whole exome sequencing. RESULTS: The notable discrepancies of somatic mutations among the 3 tumor tissues indicated that they arose independently, rather than metastasizing from 1 tumor. A novel deleterious germline mutation (chr22:29091846, G->A, p.H371Y) was identified in CHEK2, a Li-Fraumeni syndrome causal gene. Examining the status of this novel mutation in the patient's healthy siblings revealed its de novo origin. CONCLUSION: Our study reports the first case of Li-Fraumeni syndrome-like in Chinese patients and demonstrates the important contribution of de novo mutations in this type of rare disease.
JTO Clinical and Research Reports · 2023 · 3 citations · open access
NSCLC With Synchronous EGFR Mutations in Li Fraumeni Syndrome: A Case Report
AbstractWe report a case of a patient with Li Fraumeni Syndrome (LFS) who developed synchronous EGFR exon deletion 19 and EGFR exon 20 insertion NSCLC and characterize the diagnostic and therapeutic challenges in managing her care. Osimertinib was effective in the EGFR deletion 19 population but did not garner a response in the EGFR exon 20 insertion population, which was treated definitively with surgical resection. At the time of oligoprogression, she underwent surgical resection, and radiation therapy was minimized. The biologic link between LFS and EGFR mutation remains unclear, and using larger, real-world cohorts could help to clarify the relationship between LFS and EGFR- mutant NSCLC.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
